KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortization of Deferred Charges (2016 - 2022)

Travere Therapeutics (TVTX) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $428000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Amortization of Deferred Charges fell 85.17% year-over-year to $428000.0, compared with a TTM value of $1.6 million through Dec 2022, down 85.57%, and an annual FY2025 reading of $1.6 million, down 4.93% over the prior year.
  • Amortization of Deferred Charges was $428000.0 for Q4 2022 at Travere Therapeutics, roughly flat from $428000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.9 million in Q4 2021 and bottomed at $325000.0 in Q2 2018.
  • Average Amortization of Deferred Charges over 5 years is $1.9 million, with a median of $2.5 million recorded in 2019.
  • The sharpest move saw Amortization of Deferred Charges soared 661.23% in 2019, then crashed 87.65% in 2022.
  • Year by year, Amortization of Deferred Charges stood at $2.4 million in 2018, then increased by 3.64% to $2.5 million in 2019, then increased by 7.3% to $2.7 million in 2020, then rose by 7.33% to $2.9 million in 2021, then crashed by 85.17% to $428000.0 in 2022.
  • Business Quant data shows Amortization of Deferred Charges for TVTX at $428000.0 in Q4 2022, $428000.0 in Q3 2022, and $428000.0 in Q2 2022.